The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
Author:
Affiliation:
1. Department of Pulmonary Oncology, AORN dei Colli Monaldi, Naples, Italy
2. Department of Experimental Medicine Luigi Vanvitelli University, Caserta, Italy
3. Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy
Abstract
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine
Reference83 articles.
1. Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424
2. Planchard D; Popat S; Kerr K; Metastatic non-small cell lung cancer: ESMO Clinical Prac-tice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018,29(Supplement_4),iv192-37
3. Rocco D.; Della Gravara L.; Avellino A.; Immunotherapy as a targeted therapy in non-small cell lung cancer. Transl Cancer Res in press
4. Alsaab H.O.; Sau S.; Alzhrani R.; Tatiparti K.; Bhise K.; Kashaw S.K.; Iyer A.K.; PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol 2017,8,561
5. Xu-Monette Z.Y.; Zhang M.; Li J.; Young K.H.; PD-1/PD-L1 blockade: Have we found the key to unleash the antitumor immune response? Front Immunol 2017,8,1597
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events;Medical Oncology;2023-07-15
2. Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer;Expert Opinion on Biological Therapy;2023-03-04
3. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer;Frontiers in Immunology;2022-10-26
4. Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?;Expert Review of Anticancer Therapy;2022-01-20
5. Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions;Expert Review of Precision Medicine and Drug Development;2022-01-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3